This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Rio Tinto completed $2bn off-market portion of £3.2bn share buyback (shares +1.5% on ASX). The on-market $1bn portion commences 28 Feb for 1 year. Completes lease and sale deal for wharf and land with LNG Canada for $576m.
Takeda expects EU decision on Shire acquisition on/before 20 Nov, with details in due course. Subject to necessary approvals, intends to complete acquisition on 8 Jan or ASAP thereafter.
British American Tobacco and Imperial Brands may be sensitive to a Wall St Journal article suggesting that the US FDA aims to ban menthol cigarettes while Barons reported E-Cigarette setbacks as good news for big tobacco.
AstraZeneca gets FDA priority review for Lynparza for newly-diagnosed, BRCA-mutated advanced ovarian cancer following complete/partial response with 1st-line standard platinum chemotherapy. AstraZeneca gets mixed results from Farxiga DECLARE-TIMI 58 trial.
UK Index Energy companies could be sensitive to oil prices rising (Brent above $71) after Saudi Arabia urged calm and hinted at the possibility of taking as much as 1m bpd out of the market. Watch UK Index Energy names after stronger performance in Asia.
Restaurant Group announces fully underwritten 13-for-9 rights issue at 108.5p, raising gross £315m to fund part of cash payment for acquisition of Wagamama owner Mabel Topco.
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| SSE | SSE | -2.7% | -2.6% | -4.8% |
| INFORMA | INF | 2.3% | 3.3% | 0.2% |
| UNILEVER | ULVR | 1.0% | 1.2% | -0.5% |
| AO WORLD | AO/ | -11.3% | -3.7% | -12.9% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.
Prepared by Michael van Dulken, Head of Research